Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Nature
Volume 596 Issue 7872, 19 August 2021
https://www.nature.com/nature/volumes/596/issues/7872

 

Article | 30 June 2021 | Open Access
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Individuals over eighty years of age are less likely to mount a good immune response against SARS-CoV-2 (measured by neutralization titres) after the first dose of the BNT162b2 mRNA vaccine, but achieve good neutralization after the second dose.
Dami A. Collier, Isabella A. T. M. Ferreira, Ravindra K. Gupta